强肝胶囊对非酒精性脂肪性肝病患者胰岛素抵抗指数和肝纤维化评分的影响

欧强; 徐燕华; 曲立娟; 黄玲

doi:10.3969/j.issn.1001-5256.2016.10.027

强肝胶囊对非酒精性脂肪性肝病患者胰岛素抵抗指数和肝纤维化评分的影响

DOI: 10.3969/j.issn.1001-5256.2016.10.027

上海市第八人民医院感染科

详细信息

中图分类号: R575.5
计量
- 文章访问数: 2334
- HTML全文浏览量: 17
- PDF下载量: 428
- 被引次数: 0
出版历程
- 出版日期: 2016-10-20

Effect of Qianggan capsules on insulin resistance index and liver fibrosis score in patients with nonalcoholic fatty liver disease

Department of Infectious Diseases, The Eighth People′s Hospital of Shanghai

摘要

摘要:
目的观察强肝胶囊对非酒精性脂肪性肝病（NAFLD）患者肝纤维化评分和胰岛素抵抗指数的影响。方法选取2014年8月-2015年7月在上海市第八人民医院就诊的NAFLD患者85例,随机分为治疗组（n=45）和对照组（n=40）。治疗组给予强肝胶囊,对照组给予多烯磷脂酰胆碱胶囊,2组疗程均为24周。观察2组治疗前后血清转氨酶（AST、ALT）、稳态模型胰岛素抵抗指数（HOMA-IR）以及NAFLD肝纤维化评分（NAFLDFS）的变化。计量资料组间比较采用成组t检验,组内治疗前后比较采用配对t检验;计数资料组间比较采用χ2检验。结果 2组治疗后ALT、AST水平均较同组治疗前明显改善,差异均有统计学意义（P值均<0.05）;与治疗前比,治疗组HOMA-IR、NAFLDFS治疗后均明显下降,差异均有统计学意义（3.58±0.85 vs 2.48±0.78,t=6.40,P<0.05;-1.78±1.24 vs-2.35±0.98,t=2.40,P<0.05）。2组间治疗后比较,治疗组HOMA-IR、NAFLDFS较对照组显著下降,差异均有统计学意义（2.48±0.78 vs 3...
- 脂肪肝 /
- 强肝胶囊 /
- 胰岛素抗药性 /
- 肝纤维化评分
Abstract:
Objective To investigate the effect of Qianggan capsules on liver fibrosis score and insulin resistance index in patients with nonalcoholic fatty liver disease( NAFLD). Methods A total of 85 NAFLD patients who were treated in the Eighth People's Hospital of Shanghai from August 2014 to July 2015 were enrolled and randomly divided into treatment group( 45 patients) and control group( 40 patients).The patients in the treatment group were given Qianggan capsules,and those in the control group were given polyene phosphatidylcholine capsules. The course of treatment was 24 weeks for both groups. The changes in serum aminotransferases [aspartate aminotransferase( AST)and alanine aminotransferase( ALT) ],homeostasis model assessment of insulin resistance( HOMA-IR),and NAFLD fibrosis score( NAFLDFS) after treatment were observed in both groups. The t-test was used for comparison of continuous data between groups,before-after comparison within each group was made by paired t-test; and the chi-square test was used for comparison of categorical data between groups. Results Both groups showed significant improvements in ALT and AST levels after treatment( all P < 0. 01). After treatment the treatment group showed significant reductions in HOMA-IR and NAFLDFS( 3. 58 ± 0. 85 vs 2. 48 ± 0. 78,t = 6. 40,P < 0. 01;-1. 78 ±1. 24 vs-2. 35 ± 0. 98,t = 2. 40,P < 0. 01) and the treatment group had significantly lower HOMA-IR and NAFLDFS than the control group( 12. 48 ± 0. 78 vs 3. 09 ± 0. 89,t = 3. 36,P < 0. 01;-2. 35 ± 0. 98 vs-1. 48 ± 1. 08,t = 3. 80,P < 0. 01). No serious adverse events were observed during the course of treatment. Conclusion Qianggan capsules not only reduce the levels of serum aminotransferases,but also improve insulin resistance and reduce fibrosis degree in NAFLD patients.
- fatty liver /
- Qianggan capusule /
- insulin resistance /
- nonalcoholic fatty liver disease fibrosis score

HTML全文

参考文献(18)

[1]RAU M,WEISS J,GEIER A.Non-alcoholic fatty liver disease(NAFLD)[J].Dtsch Med Wochenschr,2015,140(14):1051-1055.

[2]JI XL,GE YD,AN MM,et al.Correlation analysis between nonalcoholic fatty liver disease and metabolic syndrome[J].Chin J Clin Pharmacol Ther,2014,19(6):666-670.(in Chinese)季学磊,葛艺东,安民民,等.非酒精性脂肪肝与代谢综合征的临床相关性分析[J].中国临床药理学与治疗学,2014,19(6):666-670.

[3]YAN J,XIE W,OU WN,et al.Epidemiological survey and risk factor analysis of fatty liver disease of adult residents,Beijing,China[J].J Gastroenterol Hepatol,2013,28(10):1654-1659.

[4]ANGULO P.Long-term mortality in nonalcoholic fatty liver disease:is liver histology of any prognostic significance?[J].Hepatology,2010,51(5):373-375.

[5] Fatty Liver and Alcoholic Liver Disease Study Group of the Chinese Liver Disease Association.Guidelines for diagnosis and treatment of nonalcoholic fatty liver diseases(revised in January 2010)[J].Chin J Intern Med,2010,49(3):275-278.(in Chinese)中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年1月修订)[J].中华内科杂志,2010,49(3):275-278.

[6]FRIEDMAN SL.Liver fibrosis in 2012:Convergent pathways that cause hepatic fibrosis in NASH[J].Nat Rev Gastroenterol Hepatol,2013,10(2):71-72.

[7]VERNON G,BARANOVA A,YOUNOSSI ZM.Systematic review:the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults[J].Aliment Pharmacol Ther,2011,34(3):274-285.

[8]SANAL MG.Biomarkers in nonalcoholic fatty liver disease:theemperor has no clothes?[J].World J Gastroenterol,2015,21(11):3223-3231.

[9]SHEN F,ZHENG RD,MI YQ,et al.Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients[J].World J Gastroenterol,2014,20(16):4702-4711.

[10]LEE SS,PARK SH.Radiologic evaluation of nonalcoholic fatty liver disease[J].World J Gastroenterol,2014,20(23):7392-7402.

[11]ANGULO P,HUI JM,MARCHESINI G,et al.The NAFLD fibrosis score:a noninvasive tsystem that identifies liver fibrosis in patients with NAFLD[J].Hepatology,2007,45(4):846-854.

[12]WANG Y,LIANG J,LI HY,et al.Relationship of nonalcoholic fatty liver disease fibrosis score with metabolic syndrome and its components[J].Chin J endocrirol metab,2013,29(5):406-409.(in Chinese)王玉,梁军,李洪艳,等.非酒精性脂肪肝纤维化评分与代谢综合征及其各组分的相关性研究[J].中华内分泌代谢杂志,2013,29(5):406-409.

[13]MUSSO G,GAMBINO R,CASSADER M,et al.Meta-analysis:natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity[J].Ann Med,2011,43(8):617-649.

[14]ROMBOMS K,MARRA F.Molecular mechanisms of hepatic fibrosis in Non-alcoholic steatohepatitis[J].Dig Dis,2010,28(1):229-235.

[15]WEI YC,ZHU R,XIA LL,et al.Evaluation of different indices of insulin resistance in overweight and obese population[J].Shandong Med J,2015,55(46):14-16.(in Chinese)尉耘翠,祝茸,夏丽莉,等.超重及肥胖人群中不同胰岛素抵抗计算指数准确性评价[J].山东医药,2015,55(46):14-16.

[16]LIU ZY,LYU JX.Efficacy of Qianggan capsules in treatment of nonalcoholic fatty liver disease[J].Mod J Integr Tradit Chin West Med,2014,23(6):600-601.(in Chinese)刘子永,吕俊旭.强肝胶囊治疗非酒精性脂肪肝疗效观察[J].现代中西医结合杂志,2014,23(6):600-601.

[17]GU S,HUANG MX.Clinical observation of Qianggan capsule in the treatment of non alcoholic of non-alcoholic fatty liver fibrosis[J].Chin J Hepatol,2011,19(10):791-792.(in Chinese)古赛,黄秒兴.强肝胶囊治疗非酒精性脂肪性肝纤维化的疗效[J].中华肝脏病杂志,2011,19(10):791-792.

[18]HAO LH.Effects of Qianggan capsules on clinical symptoms and liver function in patients with nonalcoholic fatty liver disease[J].J Clin Med Pract,2015,19(1):126-127.(in Chinese)郝丽红.强肝胶囊对非酒精性脂肪肝患者临床症状改善情况及肝功能的影响[J].实用临床医药杂志,2015,19(1):126-127.

施引文献

资源附件(0)

访问统计